APLS Stock Recent News
APLS LATEST HEADLINES
Apellis' (APLS) first marketed product, Empaveli, continues to be the growth driver since its launch. However, Syfovre faces some safety concerns post promising takeoff.
Astellas Pharma won FDA approval for a rival to Apellis Pharmaceuticals' eye-disease treatment and APLS stock plunged Monday.
Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding Syfovre's safety profile.
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to loss of $1.46 per share a year ago.
WALTHAM, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its second quarter 2023 financial results on Monday, July 31, 2023, at 8:30 a.m. ET.
Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with Syfovre (pegcetacoplan injection).
Down -41.23% in 4 Weeks, Here's Why Apellis Pharmaceuticals, Inc. (APLS) Looks Ripe for a Turnaround
Apellis Pharmaceuticals, Inc. (APLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Apellis Pharmaceuticals, Inc. shares dropped 37% following reports of eye inflammation cases related to its geographic atrophy treatment, Syfovre. The company reported six incidents of retinal vasculitis after administering Syfovre, which are currently under investigation. Despite the safety concerns, the FDA has not planned any immediate action, and the company's financial position remains strong, with a potential for robust long-term growth.
WALTHAM, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023, at 9:20 a.m. PT.
Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral sclerosis fails to meet primary and key secondary endpoints.